Who founded Centrexion Therapeutics?

Centrexion Therapeutics was founded by James N. Campbell in 2013.

Who are Centrexion Therapeutics's investors?

Centrexion Therapeutics's investors include Catalio Capital Management, LP, EFung Capital, New Enterprise Associates (NEA), Quan Capital, 6 Dimensions Capital, Exome Asset Management.

How much funding has Centrexion Therapeutics raised?

Centrexion Therapeutics has disclosed $178.5M raised across 11 rounds.

Where is Centrexion Therapeutics headquartered?

Centrexion Therapeutics is headquartered in Baltimore, US.

Centrexion Therapeutics

Baltimore, US · Founded 2013 · 19 employees on LinkedIn · 6 known investors

Find your way into Centrexion Therapeutics

1,523 people in our graph share verified history with the Centrexion Therapeutics team — schools, employers, funds. One of them is your warm intro.

Deep Nisharunlockedknows Mike Ward · together at University of Illinois Urbana-Champaign (overlapped)

knows the team · via Harvard University

×2knows the team · via University of Illinois Urbana-Champaign

knows the team · via Monash University

knows the team · via McDonald's Corporation

×2knows the team · via UNC Kenan-Flagler Business School

Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development. The company operates in the biotechnology and pharmaceutical industry.

Biotech Healthtech

Founders & leadership

Centrexion Therapeutics was founded in 2013 by James N. Campbell.

James N. CampbellinPresident, Chief Scientific Officer

Kerrie L. Brady inExecutiveKerrie L. Brady holds an MBA, MS in Biopharmaceuticals, and BPharm, and serves as an independent board chair and director for clinical-stage biotechnology companies, providing governance and strategic oversight on clinical development, capital planning, and investor alignment.

Gregg BeloffExecutive

Jeffrey B. Kindler inChief Executive OfficerJeffrey Kindler served as Chairman and CEO of Pfizer, where he led the company's $68 billion acquisition of Wyeth, and previously held executive roles including General Counsel at McDonald's, President of Boston Market Corp and Partner Brands, Vice President of Litigation and Legal Policy at General Electric, and Partner at Williams & Connolly. He is currently CEO of Centrexion Therapeutics, a biotherapeutics company focused on pain drug development.

Charles Oh inChief Medical OfficerCharles Oh is a physician and executive with experience in clinical development and medical affairs across pain management, cardiology, and neurology. He has led regulatory approvals for drug and medical device products in North America and Europe, and overseen clinical evaluations and medical affairs strategies for product launches.

Smital ShahinActing CBO

Mike Ward inChief Financial Officer/Chief Operations OfficerHe has spent over 25 years in investment banking focused on life sciences, advising on more than 100 financings and M&A transactions including nearly 20 IPOs, and previously served as CFO and Chief Business Officer at other life sciences companies.

Jonathan GuerrieroinChief Development Operations Officer

Board

Shengda ZanBoard director

Arnold L. OronskyBoard director

Isaac BlechBoard director

Sol BarerBoard director

Investors · 6

Catalio Capital Management, LPNew York

EFung CapitalShenzhen

New Enterprise Associates (NEA)Menlo Park · $200K – $40M

Quan CapitalShanghai

6 Dimensions CapitalreportedGrand Cayman

Exome Asset Managementreported · 2 sourcesNew York

Reported raises · per SEC filings

Form D private placements

$178.5M disclosed across 11 rounds · 2016–2023

▶$3.3MraisedJan 2024 · 116 investors · Biotechnology

Rule 506(b)